Skip to Content

Research

NEOALTTO

Research

Research

Clinicaltrial.gov identifier:
NCT00553358
Status:
Follow-up
Scenario:
Neoadjuvant
Tumour subtype:
HER2+
Phase:
Phase III
Drug/Intervention:
Lapatinib and Trastuzumab

Comparison of dual HER2 inhibition (lapatinib, trastuzumab) plus chemotherapy before surgery versus single HER2-targeted therapy

A randomized, multicenter open-label Phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2-positive primary breast cancer.

Sponsors

GlaxoSmithKline

Collaborators

Breast International Group
SOLTI

Principal investigators

José Baselga, MD, PhD

Memorial Sloan Kettering Cancer Center

Holger Eidtmann, MD

University Medical Center, Schleswig-Holstein Campus Kiel

Related publications

Article
Lapatinib with trastuzumab for Her2-positive early breast cancer (NEOALTTO): a randomised, open-label, multicentre, phase 3 trial
Article
Factors associated with surgical management following neoadjuvant therapy in patients with primary Her2-positive breast cancer: results from the NEOALTTO phase III trial
Article
Circulating tumor cells and response to neoadjuvant paclitaxel and Her2-targeted therapy: a sub-study from the NEOALTTO phase III trial
Article
Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial
Article
18F-FDGg PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in Her2-positive breast cancer: results from NEOALTTO
Article
Lapatinib with trastuzumab for Her2-positive early breast cancer (NEOALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Article
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (Her2)-targeted therapies in Her2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Article
High Her2 expression correlates with response to the combination of lapatinib and trastuzumab
Article
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in Her2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NEOALTTO trial
Article
PIK3CA mutations are associated with decreased benefit to neoadjuvant Her2-targeted therapies in breast cancer
Congress Communications
First results of the NEOALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancer.
Congress Communications
FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer patients: the NEO-ALTTO study results
Congress Communications
The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery following neoadjuvant therapy: analysis from the NEOALTTO trial
Congress Communications
Correlation between circulating tumor cells (CTCS), PET/CT and pCR in primary HER2+ breast cancer, a sub-study from the NEOALTTO trial
Congress Communications
FDG-PET/CT for early prediction of response to neoadjuvant anti-HER2 therapies in HER2-positive breast cancer (BC) patients
Congress Communications
Effective incorporation of biospecimen collection for translational studies into a phase III trial: the NEOALTTO experience
Congress Communications
PI3KCA mutations and correlation with PCR in the NEOALTTO trial (BIG 01-06)
Congress Communications
Pattern of rash, diarrhea, and hepatic toxicities secondary to neoadjuvant lapatinib and their association with age and pathological complete response (PCR) in breast cancer (BC) patients: analysis from the NEOALTTO trial
Congress Communications
The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in Her2-positive breast cancer. Survival follow-up analysis of NEOALTTO study (BIG 1-06 )
Congress Communications
10 (PTEN) evaluation in the NEOALTTO trial (BIG 01-06)
Congress Communications
EGFR expression is associated with decreased response from Her2 targeted therapeutics in the neo-adjuvant setting in the NEOALTTO trial
Congress Communications
High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NEOALTTO phase III trial
Congress Communications
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNAseq predict response to anti-Her2 treatment in the NEOALTTO trial
Congress Communications
Whole exome sequencing of pre-treatment biopsies from the NEOALTTO trial to identify DNA aberrations associated with response to Her2-targeted therapies
Congress Communications
Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in Her2 positive breast cancer: results from NEOALTTO (BIG 1-06).
Article
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Article
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.